Prescription Description
| Prescription ID | TCMF1585 |
| Pinyin Name | Er Chen Wan |
| Chinese Name | 二陈丸 |
| English Name | Erchen Pills |
| Function Description | 咳嗽 |
| Indications | None |
| Disease ICD-11 Category | |
| Human Tissues Associated with Indication | Lung |
| Reference | Chinese Classical Prescriptions |
| Reference Book/link | ISBN 7-5023-3930-2 |
Prescription Components
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH1184 | Citrus reticulata | 橘皮 | TCMH1184 | ITSAA1245-14 |
| TCMH130 | Pinellia ternata | åŠå¤ | TCMH130 | GBVT1123-13, GBVY1693-14 |
| TCMH606 | Wolfiporia cocos | 茯苓 | TCMH606 | GBPOL314-13 |
| TCMH628 | Glycyrrhiza uralensis | ç”˜è‰ | TCMH628 | ITSAM892-14 |
Targeted Human Proteins by the Ingredients of Prescription
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
| TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
| TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
| TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
| TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
| TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
| TCMT239 | PIM1 | Serine/threonine-protein kinase PIM1 | Kinase | P11309 |
| TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
| TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
| TCMT295 | MMP1 | Matrix metalloproteinase-1 | Hydrolase | P03956 |
| TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT306 | MMP2 | Matrix metalloproteinase-2 | Hydrolase | P08253 |
| TCMT321 | MMP9 | Matrix metalloproteinase 9 | Hydrolase | P14780 |
| TCMT327 | TRPV1 | Vanilloid receptor | Ion channel | Q8NER1 |
| TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
| TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
| TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
| TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
| TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
| TCMT571 | ADORA2B | Adenosine A2b receptor | GPCR | P29275 |
| TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
| TCMT599 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Transferase | P61088 |
| TCMT61 | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Unclassified | Q07820 |
| TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
| TCMT637 | SIRT3 | NAD-dependent deacetylase sirtuin 3 | Hydrolase | Q9NTG7 |
| TCMT638 | SIRT2 | NAD-dependent deacetylase sirtuin 2 | Hydrolase | Q8IXJ6 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
| TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
| TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
Targeted Pathogenic Microbes by the Ingredients of Prescription
| Target ID | Target Name |
|---|---|
| TCMT1170 | Enterobacter cloacae |
| TCMT1175 | Human immunodeficiency virus |
| TCMT1176 | Streptococcus pneumoniae |
| TCMT1178 | Actinomyces viscosus |
| TCMT1179 | Escherichia coli ATCC 8739 |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1186 | Plasmodium yoelii yoelii |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1210 | Streptococcus sobrinus |
| TCMT1211 | Fusobacterium nucleatum |
| TCMT1212 | Verticillium dahliae |
| TCMT1214 | Enterococcus faecium |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1221 | Human herpesvirus 4 |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1224 | Proteus mirabilis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1234 | Bacillus coagulans |
| TCMT1235 | Clostridium sporogenes |
| TCMT1236 | Mycobacterium bovis |
| TCMT1237 | Mycobacterium kansasii |
| TCMT1238 | Mycobacterium xenopi |
| TCMT1239 | Mycobacterium marinum |
| TCMT1243 | Aspergillus flavus |
| TCMT1245 | Phytophthora cactorum |
| TCMT1246 | Escherichia coli |
| TCMT1248 | Hepatitis C virus |
| TCMT1249 | Dengue virus 2 |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1318 | Human T-lymphotropic virus 1 |
| TCMT1321 | Staphylococcus hominis |
| TCMT1343 | Staphylococcus simulans |
| TCMT1344 | Staphylococcus sciuri |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1370 | Prevotella melaninogenica |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1393 | Vibrio sp. |
| TCMT1408 | Colletotrichum gloeosporioides |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1444 | Fusarium oxysporum |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1457 | Leishmania major |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1464 | Hepatitis B virus |
| TCMT1465 | Entamoeba histolytica |
Gene Ontology Associated to Targeted Human Proteins
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 8.42783 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, TRPV1 | 8.11029 |
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 7.30667 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.15287 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, TYR | 6.99605 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, MMP2, MMP9, PPARA, TRPV1, TYR | 6.97734 |
| [BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, TYR, XDH | 6.33711 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA7, CA9 | 6.33711 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, CA1, CA12, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FUT7, GBA2, PIM1, PPARA, TYR, XDH | 5.92988 |
| [BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, TYR | 5.86723 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, HSD11B2, HSD17B2, MCL1, MMP2, PPARA, TRPV1, TYR | 5.70275 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, PPARA, TRPV1 | 5.39351 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 5.14972 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.14972 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, TRPV1, TYR | 4.97096 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, HSD11B2, HSD17B2, MCL1, MMP2, MMP9, PPARA, TRPV1, TYR | 4.95335 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, BCL2, CA12, CA2, CA7, CDK6, CYP19A1, CYP1A1, CYP1B1, ESR1, F3, FABP3, FABP4, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MCL1, PPARA, TNKS, TNKS2, TRPV1, XDH | 4.71242 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.67397 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9, FABP3, PPARA, TRPV1 | 4.43549 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, MMP2, PPARA, TRPV1 | 4.43549 |
| [BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.43549 |
| [BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FABP4, FUT7, GBA2, HSD11B1, HSD17B2, MCL1, MMP2, MMP9, PIM1, PPARA, TNKS2, TYR | 4.23901 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.08281 |
| [BP] GO:0048522 | positive regulation of cellular process | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, MCL1, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, XDH | 3.86774 |
| [BP] GO:0016042 | lipid catabolic process | ADORA1, AKR1B10, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4, GBA2 | 3.84363 |
| [BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, GBA2, HSD11B1, HSD17B2, MCL1, MMP9, PIM1, PPARA, TYR | 3.80662 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 3.80662 |
| [BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, HSD11B1, HSD17B2, PPARA, TYR | 3.63086 |
| [BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.59438 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9, FABP3, PPARA, TRPV1 | 3.59438 |
| [BP] GO:0009056 | catabolic process | ACHE, ADORA1, AKR1B10, AOX1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2, MMP1, MMP2, MMP9, XDH | 3.55021 |
| [BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, BCL2, CDC25B, CDK6, CSNK2A1, CYP1B1, ESR1, ESRRA, F3, FABP3, MMP2, MMP9, PIM1, XDH | 3.49686 |
| [BP] GO:0048518 | positive regulation of biological process | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, MCL1, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, XDH | 3.42492 |
| [BP] GO:0044238 | primary metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, TYR, XDH | 3.35776 |
| [BP] GO:0032501 | multicellular organismal process | ADORA1, AKR1B1, AKR1B10, ALPL, BCL2, CYP19A1, CYP1A2, CYP1B1, ESR1, ESRRB, F3, FABP4, HSD11B2, HSD17B2, MCL1, MMP1, MMP2, MMP9, PIM1, PPARA, TNKS2, TRPV1, TYR | 3.35416 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, FUT7, GBA2, HSD17B1, HSD17B2, MMP1, MMP2, PIM1, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.32333 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.22853 |
| [BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 2.87511 |
| [BP] GO:0030522 | intracellular receptor signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PIM1, PPARA | 2.86564 |
| [BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, MCL1, MMP9, PTPN1, TNKS, TNKS2, XDH | 2.80141 |
| [BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, MCL1, MMP9, PTPN1, TNKS, TNKS2, XDH | 2.78531 |
| [BP] GO:0071704 | organic substance metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, TYR, XDH | 2.75228 |
| [BP] GO:0009115 | None | AOX1, XDH | 2.75026 |
| [BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 2.7296 |
| [BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, BCL2, CYP19A1, CYP1A1, CYP1B1, GBA2, TYR | 2.7296 |
| [BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.50616 |
| [BP] GO:0010035 | response to inorganic substance | AKR1B1, BCL2, CA2, CYP1A1, CYP1A2, CYP1B1, FABP4, MMP9 | 2.39749 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, AKR1B10, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2, PPARA | 2.3602 |
| [BP] GO:0043401 | steroid hormone mediated signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.3602 |
| [BP] GO:0032844 | regulation of homeostatic process | ADORA1, BCL2, CA2, CA7, CDK6, TNKS, TNKS2, TRPV1 | 2.33498 |
| [BP] GO:0046110 | None | AOX1, XDH | 2.33498 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.33498 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.33498 |
| [BP] GO:0050896 | response to stimulus | ACHE, ADORA1, ADORA3, AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, F3, FABP3, FABP4, HSD11B2, HSD17B2, MCL1, MMP2, MMP9, PPARA, PTPN1, TRPV1, TYR | 2.24717 |
| [BP] GO:0010941 | regulation of cell death | ADORA1, AKR1B1, BCL2, CSNK2A1, CYP1B1, ESR1, F3, MCL1, MMP9, PIM1, PPARA, PTPN1, TRPV1, XDH | 2.23278 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.23278 |
| [BP] GO:0032845 | None | ADORA1, BCL2, TNKS, TNKS2, TRPV1 | 2.19322 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.18552 |
| [BP] GO:0070213 | None | TNKS, TNKS2 | 2.09068 |
| [BP] GO:0006145 | None | AOX1, XDH | 2.09068 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.09068 |
| [BP] GO:0001666 | response to hypoxia | ADORA1, BCL2, CYP1A1, HSD11B2, MMP2, PPARA | 2.06985 |
| [BP] GO:0006367 | transcription initiation from RNA polymerase II promoter | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.0167 |
| [BP] GO:0042981 | regulation of apoptotic process | ADORA1, AKR1B1, BCL2, CSNK2A1, CYP1B1, ESR1, F3, MCL1, MMP9, PIM1, PTPN1, TRPV1, XDH | 2.01407 |
| [BP] GO:0008284 | positive regulation of cell proliferation | AKR1B1, BCL2, CDC25B, CDK6, CSNK2A1, ESR1, F3, MMP2, MMP9, PIM1 | 2.01407 |
| [BP] GO:0036293 | response to decreased oxygen levels | ADORA1, BCL2, CYP1A1, HSD11B2, MMP2, PPARA | 2.01407 |
| [BP] GO:0022900 | electron transport chain | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.01082 |
| [BP] GO:0048523 | negative regulation of cellular process | ACHE, ADORA1, ADORA3, AKR1B1, BCL2, CDK6, CSNK2A1, CYP19A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, MCL1, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, XDH | 2.01082 |
| [CC] GO:0044444 | cytoplasmic part | ACHE, ADORA1, AKR1B1, AKR1B10, AOX1, BCL2, CA1, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MCL1, MMP2, MMP9, PIM1, PTPN1, TNKS, TNKS2, TRPV1, TYR, XDH | 2.13216 |
| [CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2 | 1.33162 |
| [CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 1.01388 |
| [CC] GO:0000242 | None | TNKS, TNKS2 | 0.988737 |
| [CC] GO:0031233 | None | CA4, F3 | 0.988737 |
| [MF] GO:0046914 | transition metal ion binding | AOX1, CA1, CA12, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TYR, XDH | 13.2424 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 10.6608 |
| [MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PPARA, PTPN1, TNKS | 6.99605 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 6.89246 |
| [MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP1, MMP2, MMP9, PIM1, PTPN1, TNKS, TNKS2, TYR, XDH | 6.64354 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 6.06398 |
| [MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 5.80448 |
| [MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, HSD17B1, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, TYR, XDH | 5.58609 |
| [MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, TYR, XDH | 5.36818 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.96744 |
| [MF] GO:0046872 | metal ion binding | ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, PIM1, PPARA, PTPN1, TNKS, TNKS2, TRPV1, TYR, XDH | 4.95335 |
| [MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1 | 4.39855 |
| [MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.13705 |
| [MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.13705 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.84363 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 3.81328 |
| [MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 3.80662 |
| [MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.69127 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.6792 |
| [MF] GO:0008289 | lipid binding | ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, HSD11B2, HSD17B1, PPARA, TRPV1 | 3.6367 |
| [MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.63086 |
| [MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.542 |
| [MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 3.06281 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.91964 |
| [MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 2.8716 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 2.84552 |
| [MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.75026 |
| [MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.75026 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.7296 |
| [MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B2, HSD17B1, XDH | 2.29672 |
| [MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.09068 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.07346 |
KEGG Pathways Associated to Targeted Human Proteins
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA2, CA4, CA7, CA9, CA14 | 12.3201 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 10.3563 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 5.4209 |
| Metabolic pathways_Homo sapiens_hsa01100 | AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 4.8465 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.3331 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | CDK6, BCL2, PIM1, CYP1B1, MMP9, CDC25B, MCL1 | 4.0248 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.486 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, MMP1, PPARA | 3.5251 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | MMP2, BCL2, PIM1, F3 | 3.1088 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | MMP2, MMP9, ESR1, ESR2 | 3.1088 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.3378 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, PIM1, AOX1, MCL1 | 2.4613 |
| Bladder cancer_Homo sapiens_hsa05219 | MMP1, MMP2, MMP9 | 3.0241 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.4613 |
| Pathways in cancer_Homo sapiens_hsa05200 | CDK6, MMP1, MMP2, BCL2, MMP9 | 1.8847 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | ADORA3, BCL2, ADORA1 | 1.8468 |
| Hepatitis B_Homo sapiens_hsa05161 | CDK6, BCL2, MMP9 | 1.6684 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | MMP2, MMP9, ESR1 | 1.3479 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.4907 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.3479 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.4646 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.8847 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.351 |
| Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.3405 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 1.8321 |
| Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1, TRPV1 | 1.0921 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, BCL2 | 1.0917 |
| Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.2457 |
| Insulin resistance_Homo sapiens_hsa04931 | PTPN1, PPARA | 1.0921 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2 | 1.1957 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.0775 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.828 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.8655 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CDK6, BCL2, MCL1 | 0.957 |
| Apoptosis_Homo sapiens_hsa04210 | BCL2, MCL1 | 0.9767 |
| Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 0.9801 |
| Leukocyte transendothelial migration_Homo sapiens_hsa04670 | MMP2, MMP9 | 1.0551 |
| Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 1.0391 |
| cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | ADORA3, ADORA1 | 0.8655 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.7828 |
| cAMP signaling pathway_Homo sapiens_hsa04024 | ADORA1, PPARA | 0.7852 |
| Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.5849 |
| GnRH signaling pathway_Homo sapiens_hsa04912 | MMP2 | 0.5849 |
| Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | TRPV1 | 0.5787 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.5787 |
| Glioma_Homo sapiens_hsa05214 | CDK6 | 0.6295 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.624 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.5849 |
| TNF signaling pathway_Homo sapiens_hsa04668 | MMP9 | 0.5558 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.3436 |
| Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.4514 |
| Melanogenesis_Homo sapiens_hsa04916 | TYR | 0.5779 |
| Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.5849 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.5 |
| Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.6295 |
| Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.6275 |
| Rheumatoid arthritis_Homo sapiens_hsa05323 | MMP1 | 0.5849 |
| Hepatitis C_Homo sapiens_hsa05160 | PPARA | 0.5047 |
| Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.4427 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.5 |
| Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA | 0.487 |
| Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.5779 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2 | 0.4897 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.5 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.5 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | CDK6 | 0.4112 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | BCL2 | 0.5756 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.5394 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.624 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | BCL2 | 0.5382 |
| Focal adhesion_Homo sapiens_hsa04510 | BCL2 | 0.4118 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.5787 |
| Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | MMP9 | 0.4427 |
| Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.4427 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.4376 |
| Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.6332 |
| Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.6275 |
| Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.5394 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.5787 |
| Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.6295 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | CDK6 | 0.66 |
| Acute myeloid leukemia_Homo sapiens_hsa05221 | PIM1 | 0.66 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.5911 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F3 | 0.6043 |
| p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.6275 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.6275 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.7077 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.6899 |
| Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.7071 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.7077 |
| Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.7077 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | HSD11B2 | 0.76 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.8483 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8294 |
| Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.8483 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.8655 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.8595 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.2648 |
| Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 0.9801 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.0532 |
| Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.3261 |
Target Exprsssion in Healthy Human Tissues (protein & mRNA level)
Protein expression data was from the "Human Proteome Map" datasetmRNA expression data was from the "GTEx" dataset
Average Target Expression (Fold Change) in Multiple Disease Conditions
Fold Change with Corresponding Normal SamplesClick each cell within the heatmap to access gene expression of individual patient samples